Exelixis, Inc. (BIT:1EXEL)
Italy · Delayed Price · Currency is EUR | Market Cap | 12.65B +41.8% |
| Revenue (ttm) | 2.13B +9.2% |
| Net Income | 753.30M +42.9% |
| EPS | 2.79 +53.4% |
| Shares Out | n/a |
| PE Ratio | 16.79 |
| Forward PE | 14.31 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 50.21 |
| Day's Range | n/a |
| 52-Week Range | 29.27 - 53.35 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 3, 2026 |
About Exelixis
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep... [Read more]
Financial Performance
In 2025, Exelixis's revenue was $2.32 billion, an increase of 6.98% compared to the previous year's $2.17 billion. Earnings were $782.57 million, an increase of 50.13%.
Financial numbers in USD Financial StatementsNews
Exelixis Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
China-originated innovation and policy risks are shaping strategy, with a focus on novel assets and targeted AI use. Cabozantinib's growth and exclusivity are defended, while zanzalintinib is poised for multi-indication expansion. Early pipeline decisions are data-driven.
U.S. FDA extends review of Exelixis' cancer drug
The U.S. Food and Drug Administration has extended the review of Exelixis' experimental colorectal cancer drug combination by three months, the company said in a filing on Friday.
Exelixis Transcript: Citigroup’s Biopharma Back to School Summit 2026
Key priorities include expanding product franchises, especially CABOMETYX and zanzalintinib, across multiple indications and modalities. CABOMETYX shows durable growth in RCC and NETs, while zanzalintinib is positioned for major opportunities in CRC and RCC. AI-driven tools are enhancing commercial and R&D efficiency.
Exelixis Transcript: Wells Fargo 21st Annual Healthcare Conference
CABO's growth is driven by RCC and NET, with exclusivity expected until 2031 and a $3B target. Zanza is poised for immediate CRC launch, supported by strong clinical data and expanded sales force. Strategic focus includes pipeline expansion, business development, and balanced capital allocation.
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Wells Far...
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-002...
Strong Sales, Earnings Send Exelixis Shares Higher
Exelixis, Inc. (EXEL) shares enjoying institutional support – up 43.5% in a year.
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $EXEL--EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law.
EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis
Exelixis lowered and narrowed its full-year 2026 revenue guidance, citing a slower-than-expected neuroendocrine-tumor ramp -- and shares declined. SueWallSt notifies investors of a pending investigati...
Exelixis Earnings Call Transcript: Q2 2026
Q2 2026 revenues grew to $629M, with CABO franchise up 10% year-over-year and global revenues up 13%. Zanza's CRC NDA is under review, with multiple pivotal trials advancing and a robust pipeline supporting long-term growth. Guidance was lowered due to a slower NET ramp.
Exelixis Earnings release: Q2 2026
Exelixis released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Exelixis Quarterly report: Q2 2026
Exelixis has published its Q2 2026 quarterly earnings report on August 5, 2026.
Exelixis Slides: Q2 2026
Exelixis has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2026, provided an update on progress toward achieving key corporate objective...
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026 after the markets close. At...
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without ...
Exelixis Hits High on Growing Sales, Institutional Inflows
Drug adoption and a strong pipeline see institutions send Exelixis, Inc. (EXEL) shares to all-time highs.
Exelixis Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is evolving from a single to a multi-franchise model, maximizing cabo's value while preparing for zanza's launch in CRC. Robust clinical data and a focused commercial strategy drive growth, with multiple pivotal studies and early-stage assets supporting future expansion.
Exelixis Transcript: Jefferies Global Healthcare Conference 2026
The company is evolving to a franchise model, leveraging past learnings to position Zanza as a future standard of care in RCC and other cancers. Multiple pivotal studies and new diagnostics are expanding market opportunities, while capital allocation remains balanced between R&D, BD, and share buybacks.
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provi...
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in June: 2026 Jefferies...
Exelixis Transcript: Bernstein 42nd Annual Strategic Decisions Conference
The discussion highlighted a disciplined, franchise-driven strategy focused on GU and GI oncology, with zanzalintinib leading a robust pipeline and multiple pivotal trials. Collaboration, data-driven innovation, and financial strength underpin efforts to expand indications and modalities, aiming for pan-tumor leadership and sustained value creation.
Caring Men Global Partners with Exelixis to Launch “Strong Caregivers, Stronger Survivors” Caregiver Training Initiative
CHEVY CHASE, Md.--(BUSINESS WIRE)-- #Biotech--Caring Men Global, a nonprofit dedicated to supporting male caregivers facing a loved one's cancer, has received a grant from Exelixis to launch “Strong C...
Exelixis Transcript: AGM 2026
The meeting established a quorum and approved all proposals, including director elections, auditor ratification, an equity plan amendment, and executive compensation. No stockholder questions were received during the session.
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX® (cabozantinib), and its investigational oral kinase inhibitor, zanzal...